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Abstract: Obstructive Sleep Apnoea (OSA) is a common disorder in adults. Its hallmark is repetitive episodes of partial 
or complete obstruction of the upper airway during sleep associated with increasing respiratory efforts. This leads to  
oxyhaemoglobin desaturation, sleep fragmentation, and daytime symptoms, mainly excessive sleepiness. Accumulating 
evidence suggests that intermittent hypoxia and oxyhaemoglobin desaturation may, irrespective of obesity, lead to eleva-
tion of serum lipids even in non-dyslipidaemic OSA patients. Continuous Positive Airway Pressure (CPAP) is the treat-
ment of choice for OSA, since it eliminates upper airway collapse during sleep and improves sleep fragmentation, daytime 
symptoms and quality of life. Moreover, it has been proposed that the amelioration of breathing disturbances during  
sleep can improve several markers of the lipid profile, such as total cholesterol, triglycerides, low-density lipoprotein  
cholesterol, high-density lipoprotein cholesterol as well as apolipoproteins A, B and C. Indeed, some studies have   
reported improvements in these parameters especially in CPAP adherent patients. However, other studies failed to confirm 
this beneficial effect. The present article reviews the issue whether CPAP treatment exerts a beneficial effect on lipids. 
Keywords: Continuous positive airway pressure, cholesterol, lipid profile, obstructive sleep apnoea, triglycerides. 
1. INTRODUCTION 
  Obstructive Sleep Apnoea (OSA) is a common disor-
der, affecting approximately 4% of adult men and 2% of 
adult women in the general population [1]. OSA is being 
increasingly recognised as a cause of morbidity and mor-
tality [1]. 
  OSA is characterised by
 repeated episodes of complete 
or partial obstruction of the upper airway during sleep. 
Airway obstruction increases respiratory effort, and leads 
to intermittent
  arterial oxygen desaturation, systemic and 
pulmonary arterial
  blood pressure alterations, and sleep 
fragmentation [1]. Main symptoms
 include nocturnal respi-
ratory pauses, interrupted by loud
  snoring and excessive 
daytime sleepiness [1]. The gold standard for diagnosis is 
polysomnography, a simultaneous meticulous recording of 
multiple physiologic parameters, namely electroencepha-
logram, electrooculogram, electromyogram, oronasal air-
flow, chest wall and abdominal motion, body position, 
snoring, electrocardiogram and oxyhaemoglobin saturation 
[2]. 
  The definitions of sleep-related respiratory
 disturbances 
have been clarified in recent years, particularly apnoea, 
hypopnoea and respiratory effort-related arousals (RERAs) 
[2]. Apnoea is the complete cessation of airflow lasting at 
least 10 sec; hypopnoea is a discernible fall in airflow   
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lasting at least 10 sec accompanied by a decrease in oxygen 
saturation of at least 3% or by an EEG-recorded arousal; 
RERA refers to increasing respiratory effort, leading to   
an arousal from sleep, which does not meet the criteria   
for apnoea or hypopnoea [2]. Apnoea-hypopnoea index   
(AHI) is the total number of apnoeas and hypopnoeas per   
hour of sleep, and respiratory disturbance index (RDI) is the 
total number of events (e.g. apnoeas, hypopnoeas and RERAs) 
per hour of sleep [2]. RDI is generally higher than AHI,   
because the former includes RERAs, whereas the latter does 
not [2]. 
  OSA is associated with increased cardiovascular morbidity 
and mortality [1, 2]. Although it was previously assumed that 
this was due to its relation with obesity, recent data suggest 
that OSA is independently associated with the cardiovascular 
risk factors that comprise metabolic syndrome (MetS); one of 
them being dyslipidaemia [1, 2]. 
  Continuous Positive Airway Pressure (CPAP) is the treat-
ment of choice for OSA [3]. It was proven to be efficacious  
in eliminating obstructive respiratory events during sleep, 
ameliorating sleep architecture, improving daytime sleepiness 
and quality of life [4,5], and reducing serum levels of cardio-
vascular risk factors, such as total cholesterol [6] and markers 
of systemic inflammation [7]. Unfortunately, patient adherence 
to CPAP treatment remains suboptimal and its use during sleep 
time shows substantial variation [8, 9]. 
  Not only is CPAP the established treatment for OSA, but it 
may also have a favourable effect on the lipid profile in such 
patients. It has been postulated that CPAP use ameliorates in-232    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Michailidis et al. 
termittent hypoxia and reduces sympathetic nerve activity 
[10], which may account for an improved lipid profile. 
Furthermore, effective treatment of OSA may result to 
increased physical activity and a reduction of hypersomno-
lence during the day [11]. It is well known that physical 
activity can also improve serum lipid levels [12]. This   
additional therapeutic benefit is attracting considerable 
interest, but it is still under debate. Findings from numerous 
studies on the effect of CPAP treatment on lipids in OSA 
populations have been rather conflicting. This can be   
attributed to differences between the studied populations 
(i.e. dyslipidaemic, non-dyslipidaemic, obese or non-obese 
patients), the primary outcomes, the period of CPAP   
application (ranging between 1 month and 1 year) and   
patient adherence to CPAP use. 
  The present article provides a review of the current 
evidence whether CPAP treatment exerts a beneficial   
effect on lipid profile. 
2. METHODOLOGY: SEARCH STRATEGY AND 
ENDPOINTS 
  Our search strategy was based on the PubMed,   
Medscape, Embase and Google scholar databases up   
to May 2011 using combinations of the following   
keywords: Continuous positive airway pressure; lipid   
profile; dyslipidaemia; cholesterol; obstructive sleep apnoea. 
It included all types of articles (randomised controlled   
trials, original studies, review articles) written in English. 
  Treatment effect was assessed by evaluating the impact 
on serum lipids. Lipid parameters included cholesterol, 
triglycerides (TGs), low-density lipoprotein cholesterol 
(LDL-C), high-density lipoprotein cholesterol (HDL-C), 
apolipoproteins (apo) A, B and C. In many cases, lipid 
measurements were determined by enzymatic methods 
using commercial kits. Determination of cholesterol was 
performed after enzymatic hydrolysis and oxidation. LDL-
C was derived using the Friedewald equation. 
3. ASSOCIATION OF OSA WITH DYSLIPIDAEMIA 
  The link between OSA and lipid metabolism still   
remains to be defined. The repetitive episodes of upper 
airway obstruction that are characteristic of OSA result in 
intermittent hypoxia and large swings in intra-thoracic 
pressure that trigger autonomic responses, and sympathetic 
overactivity has been reported in patients with OSA   
[2]. There is a direct link between the adrenergic system 
and lipid levels and the chronic elevated sympathetic   
activity in OSA patients may lower HDL-C and increase 
serum TG levels [13, 14]. Metabolic and atherosclerotic 
changes have been previously shown in mice exposed to 
chronic intermittent hypoxia (IH) [15]. It has been demon-
strated in mice that IH induces hypercholesterolaemia by 
increasing lipoprotein secretion via upregulation of a key 
hepatic enzyme, stearoyl-coenzyme A desaturase-1(SCD-1) 
[16-18].  
  The association between OSA and lipid profile has 
been studied with conflicting results. Some findings   
suggest that OSA is independently associated with lipid 
abnormalities, while others show that dyslipidaemia is   
associated with obesity and not directly to OSA. 
  In a cross-sectional analysis of a selected group of males 
with and without OSA, Kono et al. [19] reported that OSA was 
associated with dyslipidaemia in non-obese patients, inde-
pendent of visceral fat obesity. Borgel et al. [20] demonstrated 
an influence of OSA on HDL-C levels. In their study, an inde-
pendent association was found between the change in AHI and 
the change in HDL-C or triglycerides, respectively. Can et al. 
[21] found that OSA is associated with increased lipid levels. 
Total cholesterol, LDL-C, TGs and apolipoprotein B values 
were increased in patients with OSA compared with controls 
(without OSA, p<0.05). Iesato et al. [22] reported that circulat-
ing lipoprotein lipase concentrations, which are negatively 
correlated with TG concentrations and positively correlated 
with HDL-C concentrations, were lower in OSA patients com-
pared with those in non-OSA patients. Tan et al. [23] demon-
strated that OSA subjects had greater degree of HDL dysfunc-
tion (p<0.01) and increased oxidised LDL levels (p<0.05) 
compared with controls and that AHI was the main determi-
nant of HDL dysfunction in OSA. In the Sleep Heart Health 
Study (SHHS), there was an independent association between 
the severity of OSA and HDL-C levels in females only, while 
there was only a minor but significant association with total 
cholesterol levels in males. These findings were evident in the 
age group <65 years after adjustment for co-variates [24].  
 Gruber  et al. [25] reported that OSA is associated with 
MetS independently of obesity, predominantly due to in-
creased TG levels. Zgierska et al. [26] found an independent, 
positive correlation (p<0.05) between TG levels and AHI, 
suggesting that OSA increases the risk of coronary artery dis-
ease by increasing plasma TGs, independently of obesity. Lim-
ited case-control data suggest that OSA is associated with a 
pattern of dyslipidaemia typical of the MetS. Coughlin et al. 
[27] demonstrated that OSA was independently associated 
with decreased HDL-C, increased cholesterol:HDL-C ratio and 
higher TG concentrations. Previous studies have also demon-
strated that OSA is independently associated with dyslipidae-
mia [28, 29].  
  On the other hand, McArdle et al. [30] reported an increase 
in LDL-C and total cholesterol among patients with OSA, a 
result partially explained by the presence of central obesity in 
these patients. Furthermore, Sharma et al. [31] found that OSA 
has no independent association with lipid abnormalities and 
that obesity was the major determinant of metabolic abnor-
malities in obese subjects with OSA.  
4. EFFECT OF CPAP ON SERUM LIPIDS: POSITIVE 
STUDIES 
  Several studies have provided evidence for the benefits of 
CPAP treatment on the lipid profile of OSA patients (Table 1). 
Chin et al. [32] studied the changes in lipid levels before and 
after 8 months of CPAP treatment in 22 OSA patients in corre-
lation with weight reduction, defined as BMI change >1 kg/m
2 
from baseline. In the group without body weight reduction 
(n=13), significant changes in HDL-C (p=0.013) and LDL-C 
(p=0.046) levels occurred. In the group with body weight re-
duction (n=9), there was a significant improvement in HDL-C 
(p=0.025), LDL-C (p=0.011), TGs (p=0.028), Apo A-II 
(p=0.008) and Apo C-II (p=0.021) serum levels [32]. 
 Ip et al. [29] examined the effect of 6-month CPAP treat-
ment on leptin, TGs and cholesterol levels among patients with CPAP and Lipids  The Open Cardiovascular Medicine Journal, 2011, Volume 5    233 
Table 1.  Effect of CPAP Treatment on Serum Lipids: Positive Studies 
Author, Year 
No of 
patients 
Control Group/ 
Adherence to 
CPAP (h/night) 
Baseline Lipid 
Profile 
Age 
(Years) 
BMI 
(Kg/m
2) 
AHI(/h) ESS  Duration  Methods  Results 
Chin et al. 
1999 
22 
No body weight 
reduction (n=13),  
body weight 
reduction (n=9) 
 
NBWR: 
46.2±3.7, 
BWR: 
50.8±3.7 
NBWR: 
28.5±0.8, 
BWR:31.2±1.7 
NBWR: 
52.7±5, 
BWR: 
63.5±5.8 
 8  months 
TC,  
triglycerides, 
HDL-C,  
LDL-C, apoA-I, 
apoA-II, apoB, 
apoC-II,  
apoC-III, apoE 
NBWR:  
improvement  
in HDL-C and 
LDL-C 
BWR: improve-
ment in  
triglycerides, 
HDL-C, LDL-C, 
apoA-II, apoC-II 
Ip et al. 
2000 
60 Yes   
OSA: 
43.6±10.1 
control: 
41.9±10.4 
OSA: 
27± 2.9 
control: 
26.5± 2.1 
35.7±18 
1.8±1.9 
 6  months 
TC,  
triglycerides, 
HDL-C, LDL-
C, TC/HDL-C 
ratio 
Decrease in 
triglycerides 
levels after CPAP 
treatment 
Buechner  
et al. 
2001 
95 
Effective treated 
group/ ineffective 
treated group 
LDL-C levels  
130 mg/dl 
56.6±9.5       6  months 
TC,  
triglycerides, 
HDL-C,  
LDL-C, apoB, 
and lipoprotein 
(a) levels 
Decrease in TC 
and LDL-C in 
effective treated 
group 
Robinson  
et al. 
2004 
220 
 
Yes/ 
Subtherapeutic 
CPAP 4.1±2.4, 
therapeutic CPAP 
5.0±1.9 
Mean baseline 
levels of TC 
within the 
normal range in 
both groups 
49.1±10.3 
49.7± 10.3 
35.9±6.3 
35.6±7.6 
Oxygen 
saturation 
dips 4% 
(per hour of 
sleep): 
38.5±20.3 
38.9±21.1 
16.2±3.3 
16.3±3.3 
1 year 
TC,  
triglycerides 
Reduction in TC 
in therapeutic 
CPAP group 
Borgel et al. 
2006 
127  
9.4% were under 
lipid lowering 
medication 
55.7±10.6 31.6±5.9 32.9±.21.5   6  months 
TC,  
triglycerides, 
HDL-C,  
LDL-C 
Improvement in 
TC, triglycerides, 
HDL-C, LDL-C 
levels in patients 
with initial 
abnormal  
lipids levels 
Dorkova et al. 
2008 
32 
No/ 
Good adherence 
group (5.1±1.2)  
Poor adherence 
group (1.9±1.1) 
 53.7±9.6  35.1±6.1  64±20.8  13.3±4.6  8  weeks 
TC  
triglycerides, 
HDL-C ,LDL-
C, apoA-I, apoB 
Reduction in TC 
and apoB in the 
good adherence 
group 
Barcelo et al. 
2008 
44 
Yes/ 
OSA with EDS 
(n=22), OSA 
without EDS 
(n=22) 
        3  months 
TC,  
triglycerides 
Reduction in TC 
in patients with 
EDS 
Oktay et al. 
2009 
20 
 
No  
50±7.74 
 
     1  year   
Increase in  
HDL-C 
Cuhadaroglu 
et al. 
2009 
31 
Mean CPAP use 
>4h/night 
 
Range: 28-
76 
32.3±4.7 
Range 16-
90 
11.3±5.7 8  weeks 
TC,  
triglycerides, 
HDL-C, LDL-
C, VLDL-C 
Reduction in TC 
and LDL-C 
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Table 1. contd…. 
Author, Year 
No of 
patients 
Control Group/ 
Adherence to 
CPAP (h/night) 
Baseline Lipid 
Profile 
Age 
(Years) 
BMI 
(Kg/m
2) 
AHI(/h) ESS  Duration  Methods  Results 
Steiropoulos 
et al. 
2009 
53 
Good adherence 
group 
(n=20) 
Poor adherence 
group 
(n=19) 
No CPAP group 
(n=14) 
Elevated TC 
levels (81.1%), 
elevated  
triglycerides 
levels (45.3%), 
elevated LDL-C 
levels (26.4%), 
low HDL-C 
levels (30.2%) 
46.09±10.87  34.05±7.09 56.9±26.82  11.42±5.78  6 months 
TC,  
triglycerides, 
HDL-C, LDL-
C, TC/HDL-C 
ratio,  
apoA-I, apoB, 
apoB/apoA-I 
ratio 
Reduction in TC, 
TC/HDL-C ratio 
and apoB/apoA-I 
ratio in the good 
adherence group 
Abbreviations: AHI = apnea-hypopnea index, apo = apolipoprotein, BMI = body mass index, CPAP = continuous positive airway pressure, EDS = excessive daytime sleepiness, 
HDL-C=high density lipoprotein cholesterol, LDL-C=low density lipoprotein cholesterol, TC = total cholesterol. 
severe OSA (AHI: 35.7±18). They found a significant   
decrease in serum leptin (p=0.012) and TGs (p=0.017), 
while no significant change was observed in serum   
cholesterol. 
 Buechner  et al. [33] studied the treatment effect on 
lipid levels in patients with OSA. They demonstrated a 
significant decrease in total cholesterol and LDL-C levels 
(p<0.001) after 6 months, but this occurred only in patients 
effectively treated with CPAP. 
  In a meta-analysis of 2 randomised placebo-controlled 
trials in OSA patients, Robinson et al. [34] compared the 
effect of therapeutic and subtherapeutic CPAP treatment 
on cholesterol and TGs. Despite the short treatment dura-
tion (1 month), there was a significant reduction in total 
cholesterol levels among patients receiving therapeutic 
CPAP (p=0.001), whereas no such change was observed 
among those receiving subtherapeutic CPAP. No signifi-
cant changes were observed in serum levels of TGs in ei-
ther group [34]. 
  In a large population-based study, Borgel et al. [20] 
demonstrated a small but significant increase in HDL-C 
(p<0.013) after 6 months of CPAP therapy in 127 OSA 
patients (AHI: 32.9±21.5). Furthermore, the authors   
observed significant improvements in serum levels of 
HDL-C (p<0.001), LDL-C (p<0.001), total cholesterol 
(p=0.001) and TGs (p=0.01) in OSA patients with baseline 
abnormal lipid/lipoprotein serum levels [20]. 
 Dorkova et al. [35] examined the effect of 8-week 
CPAP therapy in 32 patients with severe OSA and MetS, 
as well as the role of adherence to therapy. Adequate   
adherence was defined as use of CPAP more than 4h/night, 
while poor adherence was defined as use of CPAP for   
less than 4h/night. They observed a significant reduction  
in total cholesterol (p=0.02) and apoB (p=0.009) in   
patients with adequate adherence to treatment [35].   
Conversely, no significant changes were noted in the non-
compliant group. 
 Barcelo  et al. [36] studied 35 patients with OSA± 
excessive daytime sleepiness (EDS) who underwent CPAP 
treatment for 3 months. They found a significant decrease 
in cholesterol only in patients with EDS.  
  In an observational prospective cohort study, Oktay et al. 
[37] investigated the effect of 1-year CPAP treatment in   
patients with OSA. No significant difference was found in TG 
levels after treatment. However, a significant increase was 
observed in HDL-C (p=0.001) [37]. 
  The study of Cuhadaroglu et al. [38], examining the effects 
of 8 weeks of CPAP therapy, reported a reduction in total   
cholesterol (p<0.05) and LDL-C (p<0.05) in 31 patients with 
moderate to severe OSA who used CPAP for > 4h/night. 
  Finally, in a study from our centre [6], we examined the 
effect of compliance to CPAP therapy on serum lipids, demon-
strating significant improvements in total cholesterol 
(p=0.021), total cholesterol/ HDL-C ratio (p=0.018) and 
ApoB/ ApoA-I ratio (p=0.021) after 6 months [6]. Again, re-
ductions were only achieved in patients who were adherent to 
CPAP use (4h use per night). 
5. EFFECT OF CPAP ON SERUM LIPIDS: NEGATIVE 
STUDIES 
  There are several studies suggesting that CPAP treatment 
does not improve serum lipids (Table 2). Davies et al. [39] 
compared serum lipids of 15 not previously treated OSA pa-
tients and 18 snorers, in order to examine their association 
with coronary heart disease. OSA patients received CPAP 
treatment for more than 3 months. Levels of total cholesterol, 
TGs, very low density lipoprotein cholesterol (VLDL-C), 
LDL-C, and HDL-C of snorers and OSA patients were meas-
ured before and after CPAP treatment. There was no signifi-
cant difference in the abovementioned serum lipids when OSA 
patients before treatment and snorers were compared [39]. 
Furthermore, no change was observed in OSA after CPAP 
treatment [39]. 
  In another study in 43 OSA patients [40], it was reported 
that cholesterol levels were neither elevated at baseline   
compared with controls nor reduced by CPAP. 
 Al-Shaer  et al. [41] compared the changes in lipid profile 
between OSA patients receiving CPAP treatment (n=34)   
and those not receiving CPAP (n=28). After 126±33.7 days of 
follow-up, there was no change in lipid levels of the CPAP 
group, nor any difference between the 2 groups. CPAP and Lipids  The Open Cardiovascular Medicine Journal, 2011, Volume 5    235 
 Lattimore et al. [42] studied 10 patients with newly 
diagnosed untreated moderate to severe OSA (AHI >15/h) 
under autoCPAP treatment for 3 months. Total cholesterol, 
LDL-C and HDL-C were all within normal limits before 
CPAP treatment. There were no significant changes in se-
rum lipids after autoCPAP treatment, but this may be due, 
partly at least, to the small number of subjects. 
 Kitahara  et al. [43] found that CPAP treatment had no 
significant effect on serum total cholesterol at 2 months 
and 4 months after initiation of CPAP in patients with 
OSA. 
  In a double blind randomised controlled trial of therapeutic 
and sham CPAP for 3 months in men with type 2 diabetes and 
OSA, West et al. [44] found no significant changes in any lipid 
parameter. No differences before and after treatment were 
noted in terms of total cholesterol, HDL-C, and TGs in either 
group. 
 Drager et al. [45] studied the lipid profile of 24 patients 
with severe OSA and mild dyslipidaemia, free of comorbid-
ities who received either no treatment (n=12) or CPAP (n=12). 
No significant changes were observed in blood cholesterol, 
TGs, HDL-C, LDL-C in both groups, showing that effective 
Table 2.  Effect of CPAP Treatment on Serum Lipids: Negative Studies 
Author, 
Year 
No of 
Patients 
Control Group/ 
Adherence to 
CPAP (h/night) 
Baseline Lipid  
Profile 
Age 
(Years) 
BMI 
(Kg/m
2) 
AHI (/h)  ESS  Duration  Methods  Results 
Davies  
et al. 1994 
10 Yes 
No  
dyslipidaemia 
      >3  months 
TC,  
triglycerides 
No difference 
Barcelo  
et al.  
2004 
43 Yes             TC  No  difference 
Al-Shaer  
et al.  
2005 
62 CPAP  (n=34)        37.65   
126.2±33.7 
days 
TC,  
triglycerides 
No difference 
between the 
two groups, 
before and 
after CPAP 
Lattimore  
et al.  
2006 
10 No 
TC, LDL-C 
and HDL-C 
within normal 
limits 
49±8 
31 
(range  
24-41) 
39 
(range 
15-104) 
 3  months  TC 
No difference 
before and 
after CPAP 
treatment 
Kitahara  
et al.  
2006 
17 No          8.6±1  4  months  TC 
No difference 
before and 
after CPAP 
treatment 
West et al. 
2007 
42 
Therapeutic 
CPAP (n=20) 
Placebo CPAP 
(n=22) 
 
58 
(range  
29-74) 
55 
(range  
24-46) 
36.6  
(range  
26.2-49.2) 
36.8 
(range  
29.2-47.1) 
 
14.7±3.5 
13.6±3.5 
3 months 
TC,  
triglycerides, 
HDL-C 
No difference 
before and 
after CPAP 
treatment 
Drager  
et al. 
2007 
24 Yes 
Mild  
dyslipidaemia, 
borderline high 
levels of LDL-C 
Control: 
47±6 
CPAP: 
44±7 
Control: 
29.7±2.9 
CPAP: 
29.9±3 
Control: 
62±22 
CPAP: 
56±22 
Control: 
13±5 
CPAP: 
14±4 
4 months 
TC,  
triglycerides, 
HDL-C,  
LDL-C 
No difference 
before and 
after CPAP 
treatment 
Coughlin  
et al. 
2007 
34 
Crossover trial: 
Sham CPAP  
2.6 (0-7.5) 
Therapeutic 
CPAP  
3.9 (0-7.4) 
 49±8.3  36.1±7.6 
39.7±13.
8 
13.8±4.9 6  weeks 
TC,  
triglycerides, 
HDL-C,  
LDL-C 
No difference 
before and 
after CPAP 
treatment 
Li et al. 
2009 
20 No       
54.25±22
.78 
 90  days 
TC,  
triglycerides, 
HDL-C,  
LDL-C 
No difference 
before and 
after CPAP 
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treatment of OSA with CPAP for 4 months did not signifi-
cantly improve the lipid profile. Patients and control   
subjects presented with high borderline levels of LDL-C.  
  In a randomised blinded crossover trial in 34 obese 
Caucasians with symptoms indicating OSA, Coughlin et al. 
[46] compared the effect of 6-week therapeutic vs sham 
CPAP on serum lipids. No change was observed in terms 
of lipids in either group. Specifically, in the therapeutic 
CPAP group, there was no significant change in choles-
terol (p=0.07), TGs (p=0.33), HDL-C (p=0.15) and LDL-C 
(p=0.66) after CPAP treatment. 
 Li  et al. [47] examined the effect of 90 days of CPAP 
treatment in 20 patients, with moderate to severe OSA, 
who received nasal CPAP treatment, lasting 6 to 8 h per 
night. Comparison before and after CPAP treatment 
showed no significant changes in blood cholesterol, LDL-
C, HDL-C and TGs. 
6. EFFECT OF CPAP ON SERUM LIPIDS:   
CURRENT SITUATION AND IMPLICATIONS FOR 
FURTHER RESEARCH 
  Current evidence suggests that CPAP may exert a bene-
ficial effect on lipid profile in patients with OSA. How-
ever, this effect is not definitely proven. Indeed, there is 
data indicating that CPAP may fail to produce favourable 
changes. Based on the positive studies, CPAP may reduce 
cholesterol levels in both patients with initial normal [34] 
and abnormal lipid levels [20]. In the former, CPAP may 
improve total cholesterol, TGs, HDL-C and reduce LDL-C 
levels. Importantly, favourable changes are observed only 
in OSA patients with sufficient adherence to CPAP treat-
ment [6, 35]. Nonetheless, negative studies question the 
aforementioned beneficial effects [39-47]. It must not   
escape our notice, though, that some of the studies may  
be criticised for their small sample size [39, 42] and their 
relatively short follow-up period [34, 46]. Other limitations 
of the studies are the poor patient adherence to treatment 
[29] and the missing information regarding diet or physical 
activity [20]. 
  Clearly, the role of CPAP in the amelioration of serum 
lipids has not been defined. Results are rather conflicting, 
which may be explained by the differences in recruited 
populations, as well as in study design and endpoints. In-
deed, some works have included dyslipidaemic patients 
with OSA, under medication or not, while others patients 
with normal baseline lipids levels. The differences in re-
cruited population and baseline characteristics between the 
subjects of the studies may produce contrasting results. 
Endpoints have also been variable, including various pa-
rameters of lipid profile. Of greater significance, follow-up 
periods varied significantly, ranging from 1 month [34] to 
1 year [37]. 
  Hence, further research is necessary to re-examine the 
effect of CPAP on lipids and especially to compare the 
beneficial effect of CPAP with that of statin administra-
tion. The latter class of agents is the established treatment 
for hyperlipidaemia, while it is also increasingly being 
appreciated for its valuable pleiotropic effects [48]. It is 
important to define which patients stand to benefit and how 
long the duration of treatment is, in order to produce fa-
vourable changes. Moreover, the magnitude of the effect needs 
to be re-evaluated in comparison with the initial health status 
of patients, their adherence, lipid lowering medication, diet 
and the weight changes. Two further issues to address would 
be the potential favourable effect of CPAP on weight and insu-
lin sensitivity. Regrettably, these two parameters have largely 
been ignored in the studies included, and so it is difficult to 
determine whether any of the observed effects on lipids could 
be, at least partly, attributed to or mediated by such changes.  
  All aforementioned issues should be addressed by large-
scale randomised controlled trials. It is the authors’ opinion 
that the accumulating evidence for a positive effect of CPAP 
on lipids is very promising and warrants careful investigation. 
7. CONCLUSIONS 
  The potential benefit of CPAP treatment on the lipid pro-
file is of interest. However, it still remains under debate, due to 
the largely inconsistent results from numerous studies, recruit-
ing populations with different characteristics. This disparity is, 
partly at least, explained by the differences in studied popula-
tions, study design and primary outcomes. Such disparity fre-
quently renders meaningful conclusions difficult, as already 
shown for the effect of CPAP on glucose metabolism [49]. 
Indeed, the major limitations of most studies on the effect on 
lipids are the short follow-up period and the fact that adher-
ence to CPAP treatment, a newly recognised factor affecting 
CPAP efficacy [50, 51], was overlooked. Furthermore, the 
small size of the study samples, the diversity of the patients, 
the validity of the placebo treatment and the missing informa-
tion about the physical activities of the subjects may weaken 
study results. Hence, there is a clear need for large-scale ran-
domised, controlled studies with better adherence to therapy 
and long-term follow-up, which will allow a definite conclu-
sion regarding the effect of CPAP on the lipid profile. Such 
interventional studies will provide an answer to the question 
whether OSA is responsible for alterations in the lipid profile. 
In the meantime, CPAP still remains the established treatment 
for OSA and future research may, possibly, confirm an addi-
tional beneficial effect on lipids. 
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